Contributions
Abstract: P1119
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background: The majority of patients with multiple sclerosis (MS) will develop cognitive impairments ranging from mild abnormalities, such as compromised attention, to severe cognitive dysfunction (SCD), characterized by loss of memory and executive functions. Parkin and deglycase DJ-1 are two neuroprotective proteins that have been associated with disorders, including Parkinson's and Alzheimer's diseases, characterized by progressive neurodegeneration, cognitive impairment, and dementia.
Objectives: We surmise that parkin and DJ-1 have functional relationships with the cognitive decline observed in MS patients. The aim of this study was to identify molecular markers for SCD in MS patients.
Methods: Using quantitative immunoblotting assays, we examined the levels of parkin and DJ-1 in 28 cerebrospinal fluid (CSF) samples of (1) subjects with no MS, (2) MS patients without cognitive abnormalities, and (3) MS patients with SCD. The two groups of MS patients had similar mean scores of the expanded disability status scale (EDSS, mean 6.0).
Results: Our preliminary results indicated that, compared to the two control groups (group 1 and 2), in CSF samples of MS patients with SCD the levels of parkin were significantly reduced. Similarly, the levels of DJ-1 were decreased in CSF samples of MS patients with cognitive dysfunction in comparison with the levels detected in the two control groups. These observations were confirmed by linear regression analysis.
Conclusions: These results suggest that altered levels of neuroprotective parkin and DJ-1 are associated with cognitive decline in MS patients. Therefore, parkin and DJ-1 represent promising molecular markers for SCD in multiple sclerosis.
Disclosure:
Anna Iacoangeli: nothing to disclose. Saud A Sadiq: nothing to disclose.
Source of funding: Tisch MS Research Center of New York (private funds)
Abstract: P1119
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background: The majority of patients with multiple sclerosis (MS) will develop cognitive impairments ranging from mild abnormalities, such as compromised attention, to severe cognitive dysfunction (SCD), characterized by loss of memory and executive functions. Parkin and deglycase DJ-1 are two neuroprotective proteins that have been associated with disorders, including Parkinson's and Alzheimer's diseases, characterized by progressive neurodegeneration, cognitive impairment, and dementia.
Objectives: We surmise that parkin and DJ-1 have functional relationships with the cognitive decline observed in MS patients. The aim of this study was to identify molecular markers for SCD in MS patients.
Methods: Using quantitative immunoblotting assays, we examined the levels of parkin and DJ-1 in 28 cerebrospinal fluid (CSF) samples of (1) subjects with no MS, (2) MS patients without cognitive abnormalities, and (3) MS patients with SCD. The two groups of MS patients had similar mean scores of the expanded disability status scale (EDSS, mean 6.0).
Results: Our preliminary results indicated that, compared to the two control groups (group 1 and 2), in CSF samples of MS patients with SCD the levels of parkin were significantly reduced. Similarly, the levels of DJ-1 were decreased in CSF samples of MS patients with cognitive dysfunction in comparison with the levels detected in the two control groups. These observations were confirmed by linear regression analysis.
Conclusions: These results suggest that altered levels of neuroprotective parkin and DJ-1 are associated with cognitive decline in MS patients. Therefore, parkin and DJ-1 represent promising molecular markers for SCD in multiple sclerosis.
Disclosure:
Anna Iacoangeli: nothing to disclose. Saud A Sadiq: nothing to disclose.
Source of funding: Tisch MS Research Center of New York (private funds)